Pacritinib(Vonjo)

Another NameVonjo、LuciPac、帕克替尼

IndicationsIt is indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary myelofibrosis and a platelet count of less than 50 × 10⁹/L.